Global Abdominal Aortic Aneurysm Treatment Market Size By Type (Surgery, Medication), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

lobal Abdominal Aortic Aneurysm Treatment Market Report Description

The Global Abdominal Aortic Aneurysm (AAA) Treatment Market was valued at USD 3.4 billion in 2023 and is projected to reach USD 6.1 billion by 2031, growing at a CAGR of 7.2% during the forecast period (2023-2031).

Market growth is primarily driven by the increasing prevalence of aortic aneurysms due to aging populations, rising incidences of hypertension, atherosclerosis, and smoking-related vascular conditions. Advancements in endovascular aneurysm repair (EVAR) techniques, growing awareness about early screening, and the availability of minimally invasive treatment options are further propelling market expansion.

Drivers

✅ Rising Prevalence of Aortic Aneurysms

The aging global population is more susceptible to cardiovascular diseases, with abdominal aortic aneurysms being a significant risk. Increased screening programs are aiding early diagnosis and driving demand for treatment.

✅ Technological Advancements in EVAR

Innovations such as customized stent grafts, 3D imaging guidance, and next-gen endovascular devices are improving procedural outcomes and reducing hospital stays, boosting the adoption of EVAR over traditional open surgery.

✅ Growing Healthcare Expenditure

Emerging markets are investing in better vascular care infrastructure, expanding the accessibility of aneurysm repair procedures.

Restraints

❌ High Procedure Costs

AAA treatments, especially EVAR, involve high costs for devices, imaging, and follow-up care, limiting affordability in low-resource settings.

❌ Post-Procedure Complications & Surveillance Needs

Although minimally invasive, EVAR requires lifelong imaging follow-ups to monitor for endoleaks or stent migration, adding to long-term patient burden.

Opportunities

🌟 Adoption of Personalized & Image-Guided Surgery

Growing integration of AI, robotics, and 3D-printed grafts for precision vascular surgery is expected to open new growth avenues.

🌟 Expansion in Emerging Markets

Rising awareness about vascular diseases in Asia-Pacific & Latin America, coupled with improving reimbursement policies, offers lucrative growth prospects.

🌟 Hybrid Surgical Centers & Telemedicine Follow-ups

The development of hybrid ORs (Operating Rooms) and telemonitoring for post-surgical surveillance will enhance patient compliance and outcomes.

Market by Treatment Type Insights

Endovascular Aneurysm Repair (EVAR) dominates the market, accounting for over 70% share in 2023, due to its minimally invasive nature, reduced hospital stay, and quicker recovery.

Open Surgical Repair (OSR) still retains a segment of patients with complex anatomy unsuitable for EVAR but is gradually declining in preference.

Market by End-use Insights

Hospitals & Surgical Centers hold the largest share due to the availability of advanced imaging facilities and vascular surgeons.

Ambulatory Surgical Centers (ASCs) are expected to witness the highest growth due to the shift toward outpatient minimally invasive procedures.

Market by Regional Insights

North America leads the global AAA treatment market, driven by high disease awareness, robust healthcare infrastructure, and favorable reimbursement policies.

Europe holds a significant share due to established screening programs in countries like the UK and Germany.

Asia-Pacific is expected to register the fastest growth, fueled by rising aging population, improved healthcare infrastructure, and increasing adoption of EVAR technologies in China, India, and Japan.

Competitive Scenario

Key players include Medtronic plc, Cook Medical, Terumo Corporation, W. L. Gore & Associates, Endologix LLC, Cardinal Health, Abbott Laboratories, and Lombard Medical.

These companies focus on innovative stent graft designs, strategic partnerships with hospitals, and acquisitions to strengthen global presence.

Key recent developments:

2024: Medtronic launched a next-gen AAA stent graft with enhanced durability and reduced endoleak risk.

2023: Cook Medical expanded its EVAR product line with customized graft solutions for complex aneurysms.

2023: Terumo acquired a vascular imaging start-up to integrate AI-based guidance for EVAR procedures.

Scope of Work – Global Abdominal Aortic Aneurysm Treatment Market

Key Market Developments

Medtronic introduced a fully customizable endovascular graft for complex AAA cases in 2024.

Cook Medical partnered with leading vascular surgery networks in Europe to enhance EVAR training and adoption.

Terumo invested in AI-based intraoperative imaging solutions for improved stent placement precision.

FAQs

1) What is the current market size of the Global Abdominal Aortic Aneurysm Treatment Market?

The market was valued at USD 3.4 billion in 2023.

2) What is the major growth driver of the Global Abdominal Aortic Aneurysm Treatment Market?

The major driver is the increasing prevalence of AAA in the aging population and technological advancements in minimally invasive EVAR procedures.

3) Which is the largest region during the forecast period in the Global Abdominal Aortic Aneurysm Treatment Market?

North America is expected to remain the largest region due to high awareness and advanced healthcare facilities.

4) Which segment accounted for the largest market share in the Global Abdominal Aortic Aneurysm Treatment Market?

Endovascular Aneurysm Repair (EVAR) accounted for the largest share in 2023.

5) Who are the key market players in the Global Abdominal Aortic Aneurysm Treatment Market?

Key players include Medtronic, Cook Medical, Terumo Corporation, W.L. Gore & Associates, and Abbott Laboratories.

Would you like me to also create a visually appealing infographic summary for this report to make it more engaging? Or should I generate a full downloadable report (PDF/Word) with detailed charts and tables?